ArticleResearch and practice in thrombosis and haemostasis2025
Neonatal intracardiac thrombosis secondary to transplacental transfer of maternal antiphospholipid antibodies-a case report and review of the literature.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Maternal antiphospholipid immunoglobulin (Ig) G antibodies can cross the placenta, placing neonates at uncertain risk for thrombosis. There are no previous reports of neonatal intracardiac thrombosis (ICT) in the context of anticardiolipin antibodies (aCL). Key Clinical Question: What were the clinical manifestations, management, and outcomes for a mother and her child with ICT secondary to presumed transplacental transfer of aCL? Clinical Approach: A 2-week-old female presented with reduced feeding and was found to be poorly perfused with significant lactic acidosis. A mobile mass was noted near the left atrial appendage on the echocardiogram and confirmed on cardiac magnetic resonance imaging. Magnetic resonance imaging of the brain was normal, with no evidence of stroke. The aCL IgG titers returned highly positive for the infant (115.3 IgG phospholipid (GPL)-Unit [U]/mL) and mother (>160 GPL-U/mL; >99th percentile local reference is ≥20 GPL-U/mL). There were no other overt risk factors for thrombosis. The infant received 6 months of enoxaparin until aCL normalized. There remains a small calcified thrombus adherent to the left atrial wall. At 2 years old, the child remains healthy with no cardiac, neurologic, nor thrombotic sequelae. Conclusion: This is the first report of neonatal ICT presumed secondary to maternal aCL. The outcome was favorable with anticoagulation management. Further research is needed in the area of transplacental antiphospholipid antibody transfer, identification of neonates at risk, and optimal clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.